| |
HS
|
PD-dn
|
PD-dt
|
P
|
|---|
|
HS vs PD-dn
|
HS vs PD-dt
|
PD-dn vs PD-dt
|
|---|
|
n
|
33
|
30
|
36
|
|
Gender (M/F)
|
19/14
|
16/14
|
20/16
|
0.803
|
0.799
|
1.000
|
|
Age (years)
|
65.1 ± 11.4
|
68.2 ± 9.1
|
70.0 ± 8.1
|
0.241
|
0.133
|
0.698
|
|
UPDRS part III (score)
|
14.2 ± 7.0
|
17.3 ± 8.4
|
0.076
|
|
1–10 (n)
|
14
|
7
|
0.051
|
|
11–20 (n)
|
9
|
19
|
|
> 20 (n)
|
7
|
10
|
|
H&Y scale (stage)
|
1.4 ± 0.5
|
1.9 ± 0.8
|
0.002
|
|
1.0 (n)
|
17
|
10
|
0.014
|
|
1.5–2.0 (n)
|
12
|
17
|
|
> 2.5 (n)
|
1
|
9
|
|
LED (mg/day)
|
522.3 ± 356.5
|
|
Drugs
|
|
l-DOPA (n)
|
31a
|
|
DA agonists (n)
|
17b
|
|
Pramipexole (n)
|
8
|
|
Ropinirole (n)
|
6
|
|
Rotigotine (n)
|
3
|
|
Rasagiline (n)
|
19
|
- a15 taking l-DOPA alone, and 16 taking l-DOPA + DA agents
- b4 taking DA agonists alone (2) or with rasagiline (2), and 13 taking DA agonists + l-DOPA, without (10) or with rasagiline (3)
